The 20 Best HER-2 Positive Breast Cancer Doctors Near Me

Eric Winer is an Oncologist and a Hematologist Oncology provider in New Haven, Connecticut. Dr. Winer is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Breast Cancer in Men.

Brian Czerniecki is a General Surgeon in Tampa, Florida. Dr. Czerniecki is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, Mastectomy, and Lymphadenectomy. Dr. Czerniecki is currently accepting new patients.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer.

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.

Dr. Mothaffar F. Rimawi is a board-certified medical oncologist specializing in breast cancer care and research. He is Professor at the Department of Medicine, Section of Hematology and Oncology at Baylor College of Medicine. Dr. Rimawi is also Executive Medical Director & Associate Director of Clinical Affairs and Co-Leader of the Breast Cancer Program at BCM’s Dan L Duncan Comprehensive Cancer Center. Additionally, he serves as Chief of the Oncology Service Line at St Luke's Health in Houston.Dr. Rimawi’s professional interests include: the diagnosis, treatment and management of breast cancer; clinical trials in breast cancer; neoadjuvant therapy; targeted therapy and biomarkers in breast cancer; treatment resistance to ER and HER2-targeted therapies in breast cancer; locally advanced breast cancer; and breast disease and cancer.Dr. Rimawi received his medical degree from the University of Jordan in Amman, Jordan. He completed his residency in Internal Medicine and fellowships in Medical Oncology and Hematology and Breast Cancer at BCM. Dr. Rimawi holds certifications in Internal Medicine and Medical Oncology from the American Board of Internal Medicine. He is a member of the American College of Physicians, American Society of Clinical Oncology and the American Medical Association.In addition to English, Dr. Rimawi speaks Arabic. Dr. Rimawi is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Paget Disease of the Breast.

Elizabeth Mittendorf is a Surgical Oncologist in Boston, Massachusetts. Dr. Mittendorf is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Lymphadenectomy.

Dr. Waks received her undergraduate degree from Princeton University in 2006 and her MD degree from Harvard Medical School in 2011. She completed residency training in internal medicine at Brigham and Women's Hospital, where she subsequently served an additional year as a Chief Resident in Internal Medicine. She completed fellowship training in medical oncology at Dana-Farber/Partners CancerCare, then joined the staff of the Breast Oncology Center at Dana-Farber Cancer Institute. Dr. Waks is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma.

Francisco Esteva is an Oncologist in New York, New York. Dr. Esteva is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

My clinical practice if focused on the care of patients with breast cancer, particularly those diagnosed at a younger age and those with recurrence in the central nervous system. I am committed to the care of patients with breast cancer brain metastases, and I am honored to serve as the Medical Director of the Brain and Spine Metastases Program in the Duke Cancer Center. In this role, our multidisciplinary team provides well-coordinated care for patients with breast cancer and other solid tumor types that have metastasized to the central nervous system. In addition, I enjoy helping young women diagnosed with breast cancer navigate their treatment decisions to ensure both excellent medical care and attention to individual challenges, such as future fertility, sequelae of treatment on longer-term health, and impact on current and future relationships. When not working, I enjoy running, reading, and traveling with my family. Dr. Anders is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Brain Tumor, Triple-Negative Breast Cancer, and Metastatic Brain Tumor.

Valentina Guarneri practices in Padova, Italy. Ms. Guarneri is rated as an Elite expert by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are HER-2 Positive Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Tissue Biopsy, and Mastectomy.

Maria Dieci practices in Padova, Italy. Dieci is rated as an Elite expert by MediFind in the treatment of HER-2 Positive Breast Cancer. Their top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Tissue Biopsy, and Mastectomy.

Hope Rugo is an Oncologist in San Francisco, California. Dr. Rugo is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, Bone Marrow Aspiration, and Hormone Replacement Therapy (HRT).

Evandro De Azambuja-Azambuja practices in Brussels, Belgium. De Azambuja-Azambuja is rated as an Elite expert by MediFind in the treatment of HER-2 Positive Breast Cancer. Their top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Amenorrhea, Mastectomy, and Hormone Replacement Therapy (HRT).

Denise Yardley is an Oncologist in Nashville, Tennessee. Dr. Yardley is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Paget Disease of the Breast. Dr. Yardley is currently accepting new patients.

Nadia Harbeck practices in Koeln, Germany. Ms. Harbeck is rated as an Elite expert by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, HER-2 Positive Breast Cancer, and Mastectomy.

Sara Hurvitz is an Oncologist in Seattle, Washington. Dr. Hurvitz is rated as an Elite provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Metastatic Brain Tumor, Inflammatory Breast Cancer, and Bone Marrow Aspiration.

Giuseppe Curigliano practices in Milan, Italy. Mr. Curigliano is rated as an Elite expert by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Tissue Biopsy, and Mastectomy.

Dr. Radha Iyengar is the medical director of the Breast Center at Texas Health Presbyterian Hospital Allen. She obtained her undergraduate and medical degrees from the University of Florida and went on to complete a general surgery residency at the University of Texas Southwestern Medical School in Dallas. She then completed a Society of Surgical Oncology accredited breast fellowship at Emory University in Atlanta before returning to Texas.Dr. Iyengar is board-certified by the American Board of Surgery and is a Fellow of the American College of Surgeons. She is a member of the American College of Surgeons, Dallas Medical Society, American Society of Breast Surgeons, American Society of Breast Disease and American Society of Clinical Oncology. Dr. Iyengar is rated as an Advanced provider by MediFind in the treatment of HER-2 Positive Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Intraductal Papilloma, and Lymphadenectomy.

Dr. Walton Taylor is a general surgeon specializing in the care of patients with breast cancer and melanoma. He also performs general surgeries, including robotic and laparoscopic procedures.Dr. Taylor grew up in Dallas, Texas. He received his undergraduate degree from Vanderbilt University and attended medical school at the University of Texas Medical Branch in Galveston, Texas. After completing medical school, he returned to Dallas to complete his residency at UT Southwestern.Dr. Taylor is a former President of the American Society of Breast Surgeons. During his term as president, he oversaw the development of national guidelines for genetic testing and mammography. He continues to speak nationally on breast cancer, genetics, melanoma, and genomic testing.An active educator for fellow health care professionals, Dr. Taylor serves on Continuing Medical Education committees for the Texas Medical Association, the Accreditation Council for Continuing Medical Education, and is a member of Texas Health Physician Group's Board of Trustees and Credentialing Committee. He also aids in developing educational tools for surgeons.Dr. Taylor describes his patient-centered approach to practice with clarity and conviction. Our practice philosophy is to put patients first. We work to give next-day results to patients and provide easy access to our providers and medical staff. I give my personal cell phone number to every patient so they can contact me directly with any urgent needs or questions. We do not see patients as their medical condition, but rather we see them as people with their own unique circumstances. We are here to treat the whole person and not just focus on the medical problem. Our goal is to treat the condition and make the process as smooth as possible."". Dr. Taylor is rated as an Advanced provider by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Melanoma.

Aleix Prat practices in Barcelona, Spain. Mr. Prat is rated as an Elite expert by MediFind in the treatment of HER-2 Positive Breast Cancer. His top areas of expertise are HER-2 Positive Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Mastectomy, and Endoscopy.